Reconsidering adjuvant immunotherapy for tuberculosis

Clinical Infectious Diseases

Volumn 41, Issue 2, 2005, Pages 201-208

  Wallis, Robert S ^a,b  

^a PPD   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 2; PREDNISOLONE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

BACTERICIDAL ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; SYNDROME DELINEATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNOTHERAPY; TUBERCULOSIS, PULMONARY;

EID: 21844433456     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430914     Document Type: Review

References (77)

1. McKinney JD, Honer zu BK, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406:735-8.
2. Dubnau E, Fontán F, Manganelli R, Soares-Appel S, Smith I. Mycobacterium tuberculosis genes induced during infection of human macrophages. Infect Immun 2002; 70:2787-95.
3. Dubnau E, Smith I. Mycobacterium tuberculosis gene expression in macrophages. Microbes Infect 2003; 5:629-37.
4. Manganelli R, Dubnau E, Tyagi S, Kramer FR, Smith I. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol Microbiol 1999; 31:715-24.
5. Rodriguez GM, Smith I. Mechanisms of iron regulation in mycobacteria: role in physiology and virulence. Mol Microbiol 2003; 47:1485-94.
6. Park HD, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003; 48: 833-43.
7. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci USA 2001; 98:7534-9.
8. Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003; 198:705-13.
9. Voskuil MI, Visconti KC, Schoolnik GK. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 2004; 84:218-27.
10. Karakousis PC, Yoshimatsu T, Lamichhane G, et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 2004; 200:647-57.
11. O'Brien RJ. Scientific blueprint for tuberculosis drug development. Global Alliance for TB Drug Development. Tuberculosis 2001; 81(Suppl 1):1-52.
12. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 1993; 147:1062-3.
13. Brindle R, Odhiambo J, Mitchison DA. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1:2.
14. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360:528-34.
15. Jouanguy E, Altare F, Lamhamedi S, et al. Interferoh-gamma-recetor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-61.
16. Flesch I, Kaufmann SH. mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol 1987; 138:4408-13.
17. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175:1111-22.
18. Condos R, Rom WN, Schluger NTW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349:1513-5.
19. Giosue S, Casarini M, Ameglio F, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000; 11:99-104.
20. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, et al. Adjuvant Interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 2004; 4:44.
21. Koh WJ, Kwon OJ, Suh GY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004; 19: 167-71.
22. InterMune investor relations press release: InterMune enrolls first patient in phase III trial in multidrug-resistant tuberculosis. 2000. Available at: http://www.hopkins-tb.org/news/ 7-31-2000.shtml. Accessed 18 May 2005.
23. Raju B, Hoshino Y, Kuwabara K, et al. Aerosolized gamma Interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun 2004; 72:1275-83.
24. Johnson BJ, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997; 78:195-203.
25. Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:185-91.
26. Wallis RS, Amir Tahmasseb M, Ellner JJ. Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte Western blot. Proc Natl Acad Sci USA 1990; 87:3348-52.
27. Black RA, Rauch CT, Kozlosky CJ, et al. Á metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-33.
28. Wallis RS, Paranjape R, Phillips M. Identification by two-dimensional gel electrophoresis of a 58-kilodalton tumor necrosis factor-inducing protein of Mycobacterium tuberculosis. Infect Immun 1993; 61:627-32.
29. Valone SE, Rich EA, Wallis RS, Ellner JJ. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun 1988; 56: 3313-5.
30. Barnes PF, Chatterjee D, Abrams JS, et al. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan: relationship to chemical structure. J Immunol 1992; 149: 541-7.
31. Ribeiro-Rodrigues R, Resende CT, Johnson JL, et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 2002; 9:818-23.
32. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1990; 145: 149-54.
33. Bekker LG, Maartens G, Steyn L, Kaplan G. Selective increase in plasma tumor necrosis factor-α and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998; 178:580-4.
34. Wallis RS, Perkins M, Phillips M, et al. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J Infect Dis 1998; 178:1115-21.
35. Wallis RS, Phillips M, Johnson JL, et al. Inhibition of INH-induced expression of M. tuberculosis antigen 85 in sputum: a potential surrogate marker in TB chemotherapy trials. Antimicrob Agents Chemother 2001; 45:1302-4.
36. Aung H, Toossi Z, Wisnieski JJ, et al. Induction of monocyte expression of TNFα by the 30-kD α antigen of M. tuberculosis, and synergism with fibronectin. J Clin Invest 1996; 98:1261-8.
37. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
38. + cells in vivo during Mycobacterium tuberculosis infection. J Immunol 2004; 172: 6846-57.
39. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-7.
40. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 1994; 152:743-53.
41. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-72.
42. de Oliveira MM, da Silva JC, Amim LH, et al. Single nucleotide polymorphisms (SNPs) of the TNF-α (-238/-308) gene amongTB and non TB patients: susceptibility markers of TB occurrence? Jornal Brasileiro Pneumologia 2004; 30:461-7.
43. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257-64.
44. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995; 171:523-30.
45. 3. J Acquir Immune Defic Syndr 2003; 32:281-6.
46. Mayanja-Kizza H, Jones-Lopez EC, Okwera A, et al. Immunoadjuvant therapy for HIV-associated tuberculosis with prednisolone: a phase II clinical trial in Uganda. J Infect Dis 2005; 191:856-65.
47. East African-British Medical Research Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis: third report. Lancet 1974; 2:237-40.
48. Bilaceroglu S, Perim K, Buyuksirin M, Celikten E. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Int J Tuberc Lung Dis 1999; 3:47-54.
49. Horne NW. Prednisolone in treatment of pulmonary tuberculosis: a controlled trial. Final report to the Research Committee of the Tuberculosis Society of Scotland. Br Med J 1960; 5215:1751-6.
50. Tripathy SP, Ramakrishnan CV, Nazareth O, et al. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983; 64:73-91.
51. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11:954-63.
52. Wallis RS, Broder MS, Wong JY, Beenhouwer DO. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39:1254-6.
53. Dhillon J, Mitchison DA. Influence of BCG-induced immunity on the bactericidal activity of isoniazid and rifampicin in experimental tuberculosis of the mouse and guinea-pig. Br J Exp Pathol 1989; 70:103-10.
54. Batten JC, McCune RM Jr. The influence of corticotrophin and cortisone with antituberculous drugs on population of Mycobacterium tuberculosis in tissues of mice. Br J Exp Pathol 1957; 38:424-37.
55. Flynn JL, Chan J, Rom WN, Garay SM. Animal models of tuberculosis. Cole ST, Eisenach KD, McMurray ND, Jacobs WE, eds. Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 2004:237-50.
56. Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153-5.
57. Song XY, Fox F, Gallo MA, et al. Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation. J Infect Dis 2002; 185:204-13.
58. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-93.
59. Weiner M, Burman W, Vernon A, et al. Effect of HIV coinfection on two month sputum culture conversion and its associations with TB treatment outcomes [abstract]. Proc Am Thorac Soc 2005; 2:A20.
60. Joloba ML, Johnson JL, Namale A, et al. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4:528-36.
61. el Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998:26:1148-58.
62. Narita M, Ashkin D, Rollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-61.
63. Wallis RS, Broder MS, Wong JY, Hanson JY, Beenhouwer DO. Granulomatous infectious diseases associated with TNF antagonists. Clin Infect Dis 2004; 38:1261-5.
64. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2000. Atlanta: US Department of Health and Human Services, 2001. Available at: http:// www.cdc.gov/nchstp/tb/surv/surv2000/de fault.htm. Accessed 18 May 2005.
65. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
66. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565-70.
67. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with TNF antagonists. Arthritis Rheum 2004; 50:1959-66.
68. Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003; 37:577-81.
69. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNFα blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-7.
70. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85.
71. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-94.
72. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:22-8.
73. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-7.
74. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8.
75. Van den Brande JM, Peppelenbosch MP, van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002; 973:166-80.
76. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85.
77. Garcia Vidal C, Fernandez SR, Lacasa JM, Salavert M, Carballeira MR, Garau J. Paradoxical response to anti-tuberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:756-9.